[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obsessive-compulsive-disorder-in-adolescence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obsessive-compulsive-disorder-in-adolescence":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100486118",false,"NCT05609916","CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD","Inclusion Criteria:\n\n* The child is between the ages of 7 to 17 at enrollment with a primary diagnosis of OCD of \\> 6 months duration based on the Kiddie Schedule for Affective Disorders and Schizophrenia Lifetime Version for DSM-5 (KSADS-PL) and have a CY-BOCS ≥ 16.\n* The child is on stable and maximally tolerated SRI medication (i.e., clomipramine, fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram) for ≥12 weeks given that they are persistently and moderately symptomatic. Paroxetine is exclusionary due to safety concerns.\n* Both the child and parent participating in the study are English speaking.\n* Both the child and their parent participating in the study reside in Texas.\n\nExclusion Criteria:\n\n* The child has a diagnosis of lifetime DSM-5 bipolar disorder, psychotic disorder, and\u002For intellectual disability.\n* The child has severe current suicidal\u002Fhomicidal ideation and\u002For self-injury requiring medical intervention.\n* The child is receiving concurrent psychotherapy for OCD.\n* Initiation of a psychotropic medication less than 4 weeks prior to study enrollment or a stimulant\u002Fpsychoactive medication less than 2 weeks prior to study enrollment.","ALL","7 Years","17 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.",[25,26,27,28],"Cognitive Behavioral Therapy","Obsessive-Compulsive Disorder","Obsessive-Compulsive Disorder in Children","Obsessive-Compulsive Disorder in Adolescence","RECRUITING","2025-07-18",{"date":32,"type":33},"2025-07-20","ACTUAL",{"date":35,"type":33},"2022-11-30",{"date":37,"type":19},"2027-08-30",{"name":39,"class":40},"Baylor College of Medicine","OTHER",""]